Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivative-Mediated Intraperitoneal Photodynamic Therapy in a Canine Model
- 1 May 2020
- journal article
- research article
- Published by Wiley in Photochemistry and Photobiology
- Vol. 96 (3), 684-691
- https://doi.org/10.1111/php.13247
Abstract
Peritoneal carcinomatosis (PC) can occur as an advanced consequence of multiple primary malignancies. Surgical resection, radiation or systemic interventions alone have proven inadequate for this aggressive cancer presentation, since PC still has a poor survival profile. Photodynamic therapy (PDT), in which photosensitive drugs are exposed to light to generate cytotoxic reactive oxygen species, may be an ideal treatment for PC because of its ability to deliver treatment to a depth appropriate for peritoneal surface tumors. Additionally, epidermal growth factor receptor (EGFR) signaling plays a variety of roles in cancer progression and survival as well as PDT-mediated cytotoxicity, so EGFR inhibitors may be valuable in enhancing the therapeutic index of intraperitoneal PDT. This study examines escalating doses of benzoporphyrin derivative (BPD)-mediated intraperitoneal PDT combined with the EGFR-inhibitor cetuximab in a canine model. In the presence or absence of small bowel resection (SBR) and cetuximab, we observed a tolerable safety and toxicity profile related to the light dose received. Additionally, our findings that BPD levels are higher in the small bowel compared with other anatomical regions, and that the risk of anastomotic failure decreases at lower light doses will help to inform the design of similar PC treatments in humans.Funding Information
- University of Pennsylvania (Radiation Oncology Translational Center of Excelle)
- National Cancer Institute (P01 CA‐87971, T32 CA‐009577)
This publication has 51 references indexed in Scilit:
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Pleural MalignanciesSeminars in Radiation Oncology, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Porphyrin Bleaching and PDT-induced Spectral Changes are Irradiance Dependent in ALA-sensitized Normal Rat Skin In Vivo¶Photochemistry and Photobiology, 2007
- A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and SarcomatosisClinical Cancer Research, 2006
- C225 and PDT combination therapy for ovarian cancer: the play's the thing.JNCI Journal of the National Cancer Institute, 2005
- Photobleaching kinetics of Photofrinin vivoand in multicell tumour spheroids indicate two simultaneous bleaching mechanismsPhysics in Medicine & Biology, 2004
- Hypoxia and Photofrin Uptake in the Intraperitoneal Carcinomatosis and Sarcomatosis of Photodynamic Therapy PatientsClinical Cancer Research, 2004
- Clinical Pharmacokinetics of VerteporfinThe Journal of Clinical Pharmacology, 2002
- Photodynamic therapy of the canine peritoneum: Normal tissue response to intraperitoneal and intravenous photofrin followed by 630 nm lightLasers in Surgery and Medicine, 1991